Cargando…

Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancy

BACKGROUND: Biosimilar tumour necrosis factor inhibitors (TNFi) are increasingly used to treat inflammatory immune-mediated disorders as they cost less than the originator biologic drug. More women are therefore becoming pregnant on biosimilar TNFi. This is the first paper to explore the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scott, R, Parker, H, Mccartney, S, Harrow, P, Williams, D, Giles, I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277732/ https://www.ncbi.nlm.nih.gov/pubmed/35845229 http://dx.doi.org/10.1177/1753495X211028779

Ejemplares similares

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
por: Kim, HoUng, et al.
Publicado: (2020)

Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
por: Rezk, Mourad F., et al.
Publicado: (2020)

Correction to: Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
por: Rezk, Mourad F., et al.
Publicado: (2020)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
por: Barcina Lacosta, Teresa, et al.
Publicado: (2023)

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
por: Baumgart, Daniel C., et al.
Publicado: (2019)

Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis
por: Smolen, Josef S., et al.
Publicado: (2020)

Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2020)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future
por: Zhang, Hongtao, et al.
Publicado: (2020)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
por: Haberman, Rebecca H, et al.
Publicado: (2022)

TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System
por: Jourdain, Hugo, et al.
Publicado: (2022)

In Silico Characterization of Growth Differentiation Factors as Inhibitors of TNF-Alpha and IL-6 in Immune-Mediated Inflammatory Disease Rheumatoid Arthritis
por: Mustafa, Ghulam, et al.
Publicado: (2021)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists
por: Urbano, Paulo César Martins, et al.
Publicado: (2014)

Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
por: Stajszczyk, Marcin, et al.
Publicado: (2023)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

CLINICAL EXPERIENCE WITH INTRAVENOUS IMMUNOGLOBULIN AND TNF-A INHIBITOR THERAPIES FOR RECURRENT PREGNANCY LOSS
por: Sills, Eric Scott, et al.
Publicado: (2009)

Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)

Insights on the use of biosimilars in the treatment of inflammatory bowel disease
por: Zheng, Michael K, et al.
Publicado: (2017)

Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
por: Müskens, Wieland D., et al.
Publicado: (2019)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Attitudes of Australians with inflammatory arthritis to biologic therapy and biosimilars
por: Quinlivan, Alannah, et al.
Publicado: (2022)

Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
por: White, John, et al.
Publicado: (2018)

Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
por: Kim, Dong W., et al.
Publicado: (2023)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars
por: Gibofsky, Allan, et al.
Publicado: (2023)

Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar
por: Buurman, D. J., et al.
Publicado: (2018)

Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients
por: Kaniewska, Magdalena, et al.
Publicado: (2020)

Different Original and Biosimilar TNF Inhibitors Similarly Reduce Joint Destruction in Rheumatoid Arthritis—A Network Meta-Analysis of 36 Randomized Controlled Trials
por: Graudal, Niels, et al.
Publicado: (2019)

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
por: Müller-Ladner, Ulf, et al.
Publicado: (2023)

TNF-α/anti-TNF-α drugs and its effect on pregnancy outcomes
por: Dai, Fang-fang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aihspgl1s1efh7lk4leeoh9k0i